Nicola Fenwick BMedSc


Trial Manager

Contact details

Telephone +44 (0)121 415 8782

Fax +44 (0)121 414 3700


Cancer Research UK Clinical Trials Unit
Sir Robert Aitken Institute for Clinical Research
School of Cancer Sciences
University of Birmingham
Vincent Drive
Birmingham, B15 2TT


Nicola Fenwick is Team Manager for the Therapy Acceleration Programme (Haematology) at the Cancer Research UK Clinical Trials Unit, School of Cancer Sciences.


  • BMedSc (Hons) Medical Science 2000


Nicola Fenwick graduated with a BMedSc (Hons) from the University of Birmingham in 2000. She then went to work as a graduate technician at the Binding Site Ltd, where she was responsible for the development of diagnostic kits. She then returned to the University of Birmingham in 2004 as a Trial Monitor for the Cancer Research UK Clinical Trials Unit (CRCTU).

In 2005 Nicola was appointed as a Trial Coordinator within CRCTU and was made responsible for the management of two large, multi-centre, clinical trials looking at the effects of chemotherapy regimens in breast cancer.

She was then appointed as a Senior Trial Coordinator in 2008, leading Leukeamia and Lymphoma Research’s Early Phase Trials Team (LLR ETT). Since its inception the LLR ETT has supported over 15 UK Investigators apply for clinical grant funding for early phase clinical trials.

At the beginning of 2011 Nicola was appointed Team leader and helped secure an award to expand the LLR ETT and establish the LLR Therapy Acceleration Programme Team within CRCTU.


Research Themes

Clinical Trials. Haematology, Lymphoma, Breast Cancer

Other activities

  • National Cancer Research Institute Haemato-Oncology Clinical Studies Group Project Officer since 2008


H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas, for NeotAnGo Investigators (2009), Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR), J Clin Oncol 27:15s, 2009 (suppl; abstr 522)

Back to top